NASDAQ OMX | GlobeNewswire

http://www.globenewswire.com/newsroom/news.html?d=206660

Source: LDV Capital Management

GenSpera, InfuSystem Holding and NeoGenomics Presenting at the 2010 South Florida Biotech Dinner Conference

FORT LAUDERDALE, Fla., Nov. 10, 2010 (GLOBE NEWSWIRE) -- GenSpera (OTCBB:GNSZ), InfuSystem Holding (OTCBB:INHI) and NeoGenomics (OTCBB:NGNM) will be in Fort Lauderdale, Florida on November 10th, 2010 for the South Florida Biotech Dinner Conference, hosted by LDV Capital Management. LDV Capital Management is a Registered Investment Advisory firm licensed with the state of Florida specializing in Financial Advisory, Merger and Acquisitions, Fairness Opinions, and Investment Banking.

DINNER FORMAT:

Cocktail hour: 5:00 p.m. to 5:50 p.m.

Dinner Begins: 6:00 p.m. – followed on by coffee and dessert

Presentation 1: 6:15 p.m. to 6:45 p.m.
Presentation 2: 6:50 p.m. to 7:20 p.m.
Presentation 3: 7:25 p.m. to 7:55 p.m.
Lightning Round Closing Summary: 7:55 p.m. to 8:10 p.m.

PRESENTING COMPANIES:

GENSPERA, INC. (OTCBB:GNSZ): is a development stage oncology company focused on therapeutics that deliver a potent, unique and patented drug directly to tumors. GenSpera's technology platform combines a potent, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that releases the drug only within the tumor. Unlike standard cancer drugs, thapsigargin kills cells independent of their division rate, thus making it effective at killing all fast- and slow-growing cancers and cancer stem cells. GenSpera's prodrug platform is the subject of seven issued patents with four additional patents pending. Visit: http://www.genspera.com for more information.

INFUSYSTEM HOLDING, INC. (OTCBB:INHI): is the leading supplier of infusion services to oncologists and other outpatient treatment settings. The Company provides pole mounted and ambulatory pumps, supplies and related clinical, biomedical and billing services to practices and patients, nationwide. The Company's unique suite of services appeals to practices, patients and payors by improving access to clinically necessary medical equipment, while driving down costs and maximizing clinical outcomes. Visit http://www.infusystem.com for more information.

NEOGENOMICS, INC., (OTCBB:NGNM) is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, and hospitals throughout the United States. Visit http://www.neogenomics.com for more information.

To expedite registration, call LDV Capital Management at: 954-746-3117, www.LdvCapitalManagement.com, or email Jim@LdvCapitalManagement.com.

DISCLAIMER: LDV Capital Management is a Registered Investment Advisory firm licensed with the State of Florida. The information herein is not a solicitation to invest, but simply information compiled from company press releases and company public information. Information is believed to be reliable, but makes no representation to its accuracy or completeness. LDV does not recommend, warrant, or guarantee the success of any action taken in reliance on statements made in this news release or by any company presentations at the Conference. Due-diligence and professional advice should be sought before making any investment decisions. LDV, nor any of its principles or employees do not hold any stock positions in any of the companies mentioned above.

CONTACT: LDV Capital Management

954-746-3117

Jim@LdvCapitalManagement.com
www.LdvCapitalManagement.com